

May 9, 2024

General Announcement:

Senju Pharmaceutical Co., Ltd.

Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has started Phase III clinical trials in Japan for an in-house developed compound having the development code SJP-0008.

Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of visual field and vision loss. Approximately 90% of patients suffer severe visual impairment, resulting in less than 0.1 in decimal visual acuity ¹⁾. However, no guidelines or evidence-based therapies have been established in the world for CRAO²⁾.

Senju will work diligently to develop SJP-0008 as a new therapy for such a serious disease with the aim of obtaining manufacturing and marketing approval.

This clinical trial is to be carried out with funding under the program Cyclic Innovation for Clinical Empowerment (CiCLE) established by the Japan Agency for Medical Research and Development (AMED).

1) Hayreh SS, and Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol 2005; 140: 376–391.

2) Chronopoulos A and Schutz JS. Central retinal artery occlusion - A new, provisional treatment approach. Surv Ophthalmol. 2019; 64: 443-51.

[Contact details for inquiries]

Communications Department, Senju Pharmaceutical Co., Ltd.

3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan

Mail: cc@senju.co.jp

URL: <https://www.senju.co.jp>